Back to Search Start Over

Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance.

Authors :
Tuli, Hardeep Singh
Mittal, Sonam
Aggarwal, Diwakar
Parashar, Gaurav
Parashar, Nidarshana Chaturvedi
Upadhyay, Sushil Kumar
Barwal, Tushar Singh
Jain, Aklank
Kaur, Ginpreet
Savla, Raj
Sak, Katrin
Kumar, Manoj
Varol, Mehmet
Iqubal, Ashif
Sharma, Anil Kumar
Source :
Seminars in Cancer Biology. Aug2021, Vol. 73, p196-218. 23p.
Publication Year :
2021

Abstract

In the last few decades, targeting cancer by the use of dietary phytochemicals has gained enormous attention. The plausible reason and believe or mind set behind this fact is attributed to either lesser or no side effects of natural compounds as compared to the modern chemotherapeutics, or due to their conventional use as dietary components by mankind for thousands of years. Silibinin is a naturally derived polyphenol (a flavonolignans), possess following biochemical features; molecular formula C 25 H 22 O 10 , Molar mass: 482.44 g/mol, Boiling point 793 °C, with strikingly high antioxidant and anti-tumorigenic properties. The anti-cancer properties of Silibinin are determined by a variety of cellular pathways which include induction of apoptosis, cell cycle arrest, inhibition of angiogenesis and metastasis. In addition, Silibinin controls modulation of the expression of aberrant miRNAs, inflammatory response, and synergism with existing anti-cancer drugs. Therefore, modulation of a vast array of cellular responses and homeostatic aspects makes Silibinin an attractive chemotherapeutic agent. However, like other polyphenols, the major hurdle to declare Silibinin a translational chemotherapeutic agent, is its lesser bioavailability. After summarizing the chemistry and metabolic aspects of Silibinin, this extensive review focuses on functional aspects governed by Silibinin in chemoprevention with an ultimate goal of summarizing the evidence supporting the chemopreventive potential of Silibinin and clinical trials that are currently ongoing, at a single platform. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
1044579X
Volume :
73
Database :
Academic Search Index
Journal :
Seminars in Cancer Biology
Publication Type :
Academic Journal
Accession number :
150819359
Full Text :
https://doi.org/10.1016/j.semcancer.2020.09.014